BenchSci Revenue and Competitors
Estimated Revenue & Valuation
- BenchSci's estimated annual revenue is currently $101.6M per year.
- BenchSci received $50.0M in venture funding in January 2022.
- BenchSci's estimated revenue per employee is $217,000
- BenchSci's total funding is $997M.
Employee Data
- BenchSci has 468 Employees.
- BenchSci grew their employee count by -11% last year.
BenchSci's People
Name | Title | Email/Phone |
---|---|---|
1 | Founder and CSO | Reveal Email/Phone |
2 | Co-founder and CEO | Reveal Email/Phone |
3 | Chief Solution Architect | Reveal Email/Phone |
4 | Chief Staff, Platform | Reveal Email/Phone |
5 | Chief Staff to the CEO | Reveal Email/Phone |
6 | Chief Staff | Reveal Email/Phone |
7 | VP, Portfolio Performance Solutions | Reveal Email/Phone |
8 | VP Commercial Operations | Reveal Email/Phone |
9 | EVP | Reveal Email/Phone |
10 | VP Marketing | Reveal Email/Phone |
BenchSci Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.7M | 9 | -72% | $39.4M | N/A |
#2 | $0.9M | 11 | -83% | $23.8M | N/A |
#3 | $87.6M | 565 | 6% | N/A | N/A |
#4 | $2.8M | 18 | 13% | N/A | N/A |
#5 | $7.8M | 50 | -68% | N/A | N/A |
#6 | $13.5M | 87 | 30% | N/A | N/A |
#7 | $17.8M | 115 | -6% | N/A | N/A |
#8 | $0.9M | 11 | -39% | N/A | N/A |
#9 | $13.6M | 88 | -20% | $86M | N/A |
#10 | $20M | 129 | -12% | N/A | N/A |
What Is BenchSci?
BenchSci’s vision is to bring novel medicine to patients 50% faster by 2025. We’re achieving it by empowering scientists with the world’s most advanced biomedical artificial intelligence. For biomedical researchers and academics who are starting experiments, BenchSci offers a reagent intelligence platform that transforms published data into experiment-specific recommendations to reduce time, money and uncertainty in planning materials and methods. Unlike PubMed, Google Scholar, reagent directories, and vendors, BenchSci uses machine learning to decode open- and closed-access data, pre-print data, and data from third-party databases to present published figures with actionable insights. Backed by top-tier investors including Inovia Capital, TCV, F-Prime, Gradient Ventures (Google’s AI fund), and Golden Ventures, BenchSci's platform accelerates science at 16 top-20 pharmaceutical companies and over 4,500 leading research centers worldwide. We’re a remote-first Deloitte Tech Fast 50 and CIX Top 10 Growth company, certified Great Place to Work®, and top-ranked company on Glassdoor. Learn more at www.benchsci.com.
keywords:Biotechnology, Life Sciences, Pharmaceuticals, Machine Learning, Artificial Intelligence, Deep Learning, Science$997M
Total Funding
468
Number of Employees
$101.6M
Revenue (est)
-11%
Employee Growth %
N/A
Valuation
N/A
Accelerator
BenchSci News
Ex-Shopify CTO Jean-Michel Lemieux has joined the advisory board of BenchSci, a pharmaceutical research support company focused on cutting...
BenchSci has raised a $29 million CAD ($22 million USD) Series B funding round led by F-Prime Capital. The financing round also saw participation from Venture Capital Catalyst Initiative (VCCI) – backed Northleaf Capital Partners and return investors including Google’s AI venture fund Gradient ...
BenchSci, a Toronto, Canada-based provider of a machine learning platform to identify and resolve preclinical research inefficiencies in drug discovery, raised $22m in Series B financing. The round was led by F-Prime Capital, with participation from Northleaf Capital Partners and existing inves ...
... aiming to automate the very costly process of drug development in the pharmaceutical industry according to a recent update on BenchSci.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $76.1M | 468 | -17% | N/A |
#2 | $148.9M | 469 | 9% | N/A |
#3 | $158.6M | 470 | -1% | N/A |
#4 | $134.2M | 473 | 2% | N/A |
#5 | $60.4M | 474 | 10% | N/A |
BenchSci Funding
Date | Amount | Round | Lead Investors | Reference |
---|---|---|---|---|
2018-05-03 | $10.0M | A | Inovia Capital | Article |
2020-02-04 | $22.0M | B | F-Prime Capital | Article |
2022-01-24 | $50.0M | C | Inovia Capital, TCV | Article |